Biopharma | June 05, 2026
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
A one-shot gene-editing cholesterol therapy could soon be a reality
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The country’s strength lies not just in technology availability but in adoption behaviour
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
